anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
HAART is a potent suppressor of plasma and lymph node HIV RNA. However, studies suggest that HAART cannot significantly diminish reservoirs of chronically HIV-infected cells. Strategies designed to eradicate all HIV infection should seek to actively target these reservoirs. CTX administration has been shown to eliminate a large number of lymphoid tissue T cells and macrophages, appearing to actively target chronically HIV-infected cells. As lymphoid organs are repopulated following initial depletion with CTX, HAART may protect repopulating cells from becoming HIV-infected, resulting in a net additional removal of the HIV-infected lymphoid reservoir.

In Step 1 of this 2-step protocol, all patients receive a HAART regimen of nelfinavir (NFV) plus stavudine (d4T) plus lamivudine (3TC). Patients who achieve an acceptable virologic response, defined as 2 consecutive HIV RNA determinations below 500 copies/ml at least 2 weeks apart between Weeks 4 and 16 of Step 1 \[AS PER AMENDMENT 10/30/98: defined as 2 consecutive plasma HIV RNA determinations below 50 copies/ml by the Roche Ultrasensitive assay within a 4-week period between Weeks 4 and 24\], are randomized to Arm A or B of Step 2. In Arm A, patients receive NFV plus d4T plus 3TC. In Arm B, patients receive NFV plus d4T plus 3TC plus 3 escalating doses of CTX at 6-week intervals. Patients in both arms are followed for at least 52 weeks following randomization to Step 2. During this time, patients undergo blood tests and lymph node biopsies to measure HIV DNA and RNA levels and to characterize the T cell population. Additionally, patients undergo a chest CT of the thymus before randomization to Step 2 and at Week 52 of Step 2. Cerebrospinal fluid may be obtained at Week 52 to determine the amount of HIV RNA and DNA present. \[AS PER AMENDMENT 10/30/98: G-CSF is given after the first dose of CTX, at the discretion of the investigator, and after the second and third doses, for up to 14 days, until the absolute neutrophil count is 10,000 cells/mm3. Also, CTX doses may be modified based on pharmacokinetic study results.\]
The present invention provides biologically active variants of human α-2b-interferon. The variants contain carboxy terminus truncations when compared with the amino acid sequence of full-length human α-2b-interferon. It is the novel finding of the present invention that these truncated variants have the biological activity of full-length human α-2b-interferon. The invention encompasses these biologically active variant α-interferons, as well as polynucleotides encoding these interferons. Expression cassettes comprising these polynucleotides and host cells comprising the expression cassettes are also provided. The invention also provides compositions comprising variant α-interferon polypeptides and a pharmaceutically acceptable carrier.
Use of topical compsn. contg. 0.2-25 wt.% omega-3-fatty acid, esp. eccosapentaenoic acid (EPA) or its physiologically acceptable salts or ester (in pure form or as a component of fish oil), plus usual auxiliaries and additives for treatment of burns is new. EPA is present as highly purified fish oil concentrate contg. at least 25 wt.% EPA (expressed in terms of methyl esters) and derived from cold-water fish such as mackerel, sardine, herring or salmon. USE/ADVANTAGE - The compsns. provide rapid healing of burns with almost no side effects. EPA probably inhibits inflammatory mediators and, unlike omega-6 fatty acids, penetrates the skin rapidly without needing a penetration enhancer. EPA is already known for treatment of abnormal skin pigmentation, psoriasis, eczema, periodontitis, alopecia seborrhoea, impotence, inflammation, etc.
The present invention relates to formulations of azelaic acid esters and other dicarboxylic acid esters, and their derivatives. In preferred embodiments, the esters have the general Formula (I) wherein R1 and R2 are selected from hydrogen, alkyl groups of up to about 18 carbon atoms and aryl groups of up to about 18 carbon atoms and alkylene group of up to about 18 carbon atoms and an arylene group of up to about 18 carbon atoms. The alkyl, aryl, alkylene and aryl groups may be substituted or unsubstituted, branched or straight chains. In addition, R1 and R2 may contain heteroatoms and may be straight chained or branched, n is an integer from 1-16, and R1 and R2 are not simultaneously hydrogen. R2OOC-(CH2)n-COOR1 (I). The azelaic acid derivatives of Formula (I) of this invention are certain derivatives of azelaic acid and other alkyl geminal diacids which possess a desirable high lipophilicity and biphasic solubility in comparison to the parent compound, azelaic acid, and which are cleaved enzymatically to azelaic acid. Compounds produced from the compounds of Formula (I) by the enzymatic hydrolysis of the R1 and R2 groups are useful as anti-bacterial agents in mammals in vivo and have been contemplated to be used in the treatment of skin disease.
Anemia reduction efforts have largely focused on increasing iron intakes such as improving diet quality, food fortification with iron, iron supplementation, biofortification. There is little information on the contribution of menstrual iron loss to iron deficiency anemia.

Indeed, the accurate measurement of menstrual blood loss volume and iron loss is difficult. Self-perception of heavy menstrual blood loss poorly predicts actual blood loss, and the objective measurement of menstrual blood loss remains a tedious method. Various methods have been used to objectively measure menstrual blood loss volume including radioisotopes, but these methods are invasive. The investigators aim to validate a much simpler technique, namely the stable iron isotope dilution methodology. This is a promising new method for quantifying long-term body iron balance, absorption, and loss which has not been applied previously to measure menstrual iron losses. Validating this new method against the alkaline hematin reference method would be an important step to encourage menstrual blood loss measurements and shed light on the contribution of menstrual blood loss to iron deficiency and iron deficiency anemia.
FIELD: medicine.SUBSTANCE: invention relates to medicine, in particular to surgery, and can be used in traumatology and orthopedics, namely, to a method for manufacturing a cement spacer for etiotropic local antibacterial therapy for infectious affections of bones and joints. The method involves mixing a polymethylmethacrylate powder of bone cement containing gentamicin with a broad-spectrum antibiotic and with Poviargolum. At the same time, an individually selected water-soluble thermostable antibiotic in the amount of 10 wt. % is additionally injected intraoperatively into the bone cement with gentamicin in the form of a powder and, with the necessary duration of antimicrobial activity for 21 days, Poviargolum powder is used in an amount of 2.5 wt. % or in the amount of 10 wt. % if the required duration of antimicrobial activity is more than 21 days. Then a liquid monomer of bone cement based on methyl methacrylate is added and mixed until a paste of a dough-like consistency is obtained, after which the spacer components are made.EFFECT: ensuring the possibility of individual selection of local etiotropic antibacterial therapy, the implementation of the necessary duration of effective antimicrobial action of the spacer, the prevention of the formation of microbial biofilms on the surface of the structure, as well as the elimination of technical problems when removing the implant at the stages of surgical treatment while maintaining sufficient strength characteristics of the spacer.1 cl, 2 ex, 4 dwg
A pharmaceutical product comprises the use of a combination of tyrosine and iron for separate, sequential or simultaneous administration for the treatment of Parkinson's disease or depression. In a preferred embodiment the product also contains at least one of a vitamin B6 (e.g. pyridoxine), a folate (e.g. folic acid), a vitamin B3 (e.g. nicotinamide), or zinc. The product enables the natural biosynthesis, secretion, transport and action of dopamine.
The present invention addresses the problem of providing a nitrogen-containing compound effective for inhibiting cancer stem cell proliferation.　The problem is solved by a nitrogen-containing compound represented by general formula (I), or a pharmaceutically acceptable salt thereof: [Chemical formula 1] (here, m and n are the same or different and represent an integer of 1 to 3. R1 and R2 are the same or different and represent a hydrogen atom, a C1-6 linear or branched alkyl group optionally having a halogen atom as a substituent, a C1-6 linear or branched alkoxy group, a halogen atom, an amino group, a hydroxyl group, a nitro group, a carboxy group, or a cyano group. R3 represents a C1-6 branched or linear alkyl group optionally having a halogen atom as a substituent. X1, X2, and X3 represent a carbon atom or a nitrogen atom, and one or two of X1, X2, and X3 are nitrogen atoms. X4 represents a carbon atom or a nitrogen atom. However, excluding (i) the situation in which X1 and X4 are both nitrogen atoms and X2 and X3 are both carbon atoms and (ii) the situation in which X3 and X4 are both nitrogen atoms and X1 and X2 are both carbon atoms.).
A composition for preventing and treating cognitive dysfunction is provided to suppress the nerve cell toxicity which is induced by a beta-amyloid and recover memory damage caused by a scopolamine. A pharmaceutical composition for preventing and treating diseases related to cognitive dysfunction comprises a sulforaphane of the structural formula (I) as an active ingredient. The diseases related to the cognitive dysfunction are alzheimer dementia, intracerbroventricular dementia, Pick disease, Creutzfeldt-jakob disease and Parkinson disease. The compound is contained in the content of 0.1-50 weight%. A health functional food for preventing and treating the diseases related to the cognitive dysfunction comprises the sulforaphane as an active ingredient. The health functional food is used in a form of tablet, capsule, pill and liquid.
Alzheimer's disease (AD) is the most common form of dementia and is characterized by the accumulation of amyloid β (Aβ) and phosphorylated tau. Neuroinflammation, mainly mediated by glial activation, plays an important role in AD progression. Although there is growing evidence for the anti-neuroinflammatory and neuroprotective effects of the cannabinoid system modulation, the detailed mechanism remains unclear. To address these issues, we analyzed the expression levels of cannabinoid receptor type II (Cnr2/Cb2) in AppNL-G-F/NL-G-F mice and human AD precuneus, which is vulnerable to amyloid deposition in AD, and the effects of JWH 133, a selective CB2 agonist, on neuroinflammation in primary glial cells and neuroinflammation and cognitive impairment in AppNL-G-F/NL-G-F mice. The levels of Cnr2/Cb2 were upregulated in microglia isolated from the cerebral cortex of AppNL-G-F/NL-G-F mice. CNR2 expression was also increased in RNAs derived from human precuneus with advanced AD pathology. Chronic oral administration of JWH 133 significantly ameliorated the cognitive impairment of AppNL-G-F/NL-G-F mice without neuropsychiatric side effects. Microglia and astrocyte mRNAs were directly isolated from the mouse cerebral cortex by magnetic-activated cell sorting, and the gene expression was determined by quantitative PCR. JWH 133 administration significantly decreased reactive astrocyte markers and microglial C1q, an inducer for the reactive astrocytes in AppNL-G-F/NL-G-F mice. In addition, JWH133 administration inhibited the expression of p-STAT3 (signal transducer and activator of transcription 3) in astrocytes in AppNL-G-F/NL-G-F mice. Furthermore, JWH 133 administration suppressed dystrophic presynaptic terminals surrounding amyloid plaques. In conclusion, stimulation of microglial CB2 ameliorates cognitive dysfunction in AppNL-G-F/NL-G-F mice by controlling astrocyte activation and inducing beneficial neuroinflammation, and our study has implications that CB2 may represent an attractive therapeutic target for the treatment of AD and perhaps other neurodegenerative diseases involving neuroinflammation.
The invention relates to the technical field of immunotherapy, in particular to application of a compound in preparing a medicament for promoting T cell infiltration. The structural formula of the compound is shown as a formula (1). The inventor carries out in vitro screening on hundreds of compounds, and finds that the compound with the chemical formula as formula (1) has stronger capability of promoting T cell activation and can start the transcriptional activation of NFAT pathway of a screening system. The inventor further uses the compound in vivo experiments of mice, and finds that the compound can effectively promote the infiltration of T cells of a C26 tumor cell-bearing mouse model at tumor tissues. Therefore, the compound can be used for adjusting tumor immune environment and promoting T cells to infiltrate into solid tumor tissues, thereby creating a material basis for immunotherapy. The technical scheme can solve the technical problems that the solid tumor is difficult to be infiltrated by immune cells and the CAR-T therapy in the prior art cannot effectively treat the solid tumor, and has ideal application prospect in emerging immunotherapy.
The present invention relates to the use of lactic acid bacteria strains in combination to enhance the gastrointestinal barrier function. A combination of lactic acid bacteria strains is disclosed which can be used to enhance the gastrointestinal barrier function and/or to ameliorate diseases associated with abnormal gastrointestinal barrier function. The invention also discloses that the lactic acid bacteria strain combination can be used for inhibiting the growth of pathogenic bacteria in the gastrointestinal tract. Wherein the lactic acid bacteria strain combination comprises a composition having a composition profile falling within the range of 1:0.2:0.67 to 1:9: lactobacillus rhamnosus MP108 (CGMCC No. 21225), bifidobacterium longum subspecies infancy BLI-02 (CGMCC No. 15212) and bifidobacterium animalis subspecies lactis BB-115 (CGMCC No. 21840) with a bacterial count ratio within 9.
Group B will be prepared before the operation with a 24-hour fasting. This is the current clinical standard.
Parent training programs aimed at improving language outcomes for children with complex communication needs have predominantly been evaluated on child-centered outcomes and less often on the impact on social life or parental well-being. This study examined parent perceptions of social life before and after ComAlong, a group intervention providing parents with knowledge and training in responsive communication, environmental-milieu teaching strategies and augmentative and alternative communication (AAC). Parents (N = 467) completed questionnaires during the first and last sessions of ComAlong groups held in Sweden 2012 to 2018. Main outcome measure was change in the Social Life Scale from the Family Impact Questionnaire. Associations between this measure and demographic factors of parents and children were analyzed, along with reported change in parents' use of AAC. Pre-post comparisons revealed small significant positive changes in perceived impact of social life following intervention. The magnitude of the positive change was larger among parents of children with non-syndromic diagnoses and parents of children with autism spectrum disorder or attention deficit hyper activity disorder (ADHD). Differences in social life impact was not associated with parents' gender, language proficiency, age, or educational background. In conclusion, communication-focused parent training programs can have a positive impact on social family life and may thereby influence children's participation.
Data will be collected in the waiting room before cholecystectomy surgery. A pre-test will be performed 30 minutes before the patient enters the operation. General Comfort Scale, Surgical Fear Scale and Stress Rating Scale will be applied 30 minutes before the operation. Stress ball application will be made to the patient for 15 minutes. At the end of the stress ball application, General Comfort Scale, Surgical Fear Scale and Stress Rating Scale will be applied to the patients again.
Participants with PD will be studied at initial visit assessing clinical, cognitive, and brain imaging. A one year and, if applicable, three year cognitive assessment will be done, and the entire/complete assessment (same as initial visit) will be repeated again at two years. There will be a maximum of three follow up visits. The imaging test battery will consist of amyloid and acetylcholine brain PET and MRI scans. The use of acetylcholine PET imaging will demonstrate how changes in activity of this neurotransmitter relate to changes in cognitive functions, such as memory and mental concentration. A key question will be whether persons with PD who not only are losing acetylcholine brain cells but also have the buildup of the Alzheimer amyloid protein have a more rapid progression with more severe cognitive decline and behavioral changes compared to persons who do not have the amyloid protein.
BACKGROUND: Working long consecutive hours' is common for anaesthesia and critical care physicians. It is associated with impaired medical reasoning's performance of anaesthesiology and serious medical errors. However, no study has yet investigated the impact of working long consecutive hours' on medical reasoning.
OBJECTIVE: The present study evaluated the impact of working long consecutive hours' on the medical reasoning's performance of anaesthesiology and intensive care physicians (residents and seniors).
METHODS: This multicentric, prospective, cross-over study was conducted in 5 public hospitals of Normandy region. Two groups of anaesthesia and critical care physicians were formed. One was in a rest group, RG (after a 48-hours weekend without hospital work) and the other in Sleep Deprivation Group (SDG) after a 24 h-consecutives-shift. Changes in medical reasoning's performance were measured by 69-items script concordance tests (SCT) through to the two tests. Group A completed the first part of the assessment (Set A) after a weekend without work and the second part (Set B) after a 24 h-shift; group B did the same in reverse order. The primary outcome was medical reasoning's performance as measured by SCT in RG and SDG. The secondary outcomes included association between the performance with the demographic data, variation of the KSS (Karolinska sleepiness scale) daytime alertness score, the number of 24 h-shift during the previous 30 days, the vacations during the previous 30 days, the presence of more or less than 4 h consecutives hours slept, the management of a stressful event during the shift, the different resident years, the place where the shift took place (University hospital or general hospitals) and the type of shift (anaesthesia or intensive care).
RESULTS: 84 physicians (26 physicians and 58 residents) were included. RG exhibited significantly higher performance scores than SDG (68 ± 8 vs. 65 ± 9, respectively; p = 0.008). We found a negative correlation between the number of 24 h-shifts performed during the previous month and the variation of medical reasoning's performance and no significant variation between professionals who slept 4 h or less and those who slept more than 4 h consecutively during the shift (-4 ± 11 vs. -2 ± 11; p = 0.42).
CONCLUSION: Our study suggests that medical reasoning' performance of anaesthesiologists, measured by the SCT, is reduced after 24 h-shift than after rest period. Working long consecutive hours' and many shifts should be avoided to prevent the occurrence of medical errors.
FIELD: medicine, cardiology, phytotherapy. SUBSTANCE: invention relates to the development of the preparation "Kardiofit" used for treatment of patients with cardiovascular diseases. Preparation provides cardiotonic, coronarolytic, hypotensive, antihypoxic, antithrombic and sedative effects and excludes the appearance of adverse effects. Preparation has a tincture consisting of 14 medicinal plants prepared on 40% ethyl alcohol. Preparation shows good therapeutic effect, promotes the retention of optimal working capability, decreases the development of diencephalic damages and improves the body state at physical loading. EFFECT: enhanced effectiveness of the preparation. 1 cl, 4 tbl
In Part 1b, a single dose of HTL0016878 will be administered to 6 subjects on two occasions: once in the fasted and once the fed state. This will be open-label. Healthy, young, male or female subjects.
Placebo is administered intravenously during seven dose levels. Levels 1 - 3 include one subject per level and levels 4 - 7 include two subjects per level (1 sentinel + 1 subject).
This invention pertains to therapeutic acne treating-wound healing compositions useful for the topical treatment of acne vulgaris. The compositions comprise a therapeutically effective amount of tretinoin and a wound healing composition. In one embodiment the wound healing composition comprises (a) pyruvate; (b) an antioxidant; and (c) a mixture of saturated and unsaturated fatty acids. The therapeutic acne treating-wound healing compositions may be utilized in a wide variety of pharmaceutical products. This invention also relates to methods for preparing and using the therapeutic acne treating-wound healing compositions and the pharmaceutical products in which the therapeutic compositions may be used. This invention also relates to methods for employing the therapeutic acne treating-wound healing compositions to treat wrinkles.
BACKGROUND: Numerous studies have demonstrated that the onset of type 2 diabetes (T2D) is linked to the reduction in ß-cell mass caused by apoptosis, a process initiated by endoplasmic reticulum (ER) stress. The aim of this study was to investigate the associations between single nucleotide polymorphisms (SNPs) in the ATF6 gene (activating transcription factor 6), a key sensor of ER stress, and T2D susceptibility.
METHODS: The study involved 3229 unrelated individuals, including 1569 patients with T2D and 1660 healthy controls from Central Russia. Four functionally significant intronic SNPs, namely rs931778, rs90559, rs2341471, and rs7517862, were genotyped using the MassARRAY-4 system.
RESULTS: The rs2341471-G/G genotype of ATF6 was found to be associated with an increased risk of T2D (OR = 1.61, 95% CI 1.37-1.90, PFDR < 0.0001). However, a BMI-stratified analysis showed that this genotype and haplotypes CGGA and TAGA are associated with T2D risk exclusively in subjects with obesity or overweight (PFDR < 0.05). Despite these patients being found to have higher consumption of high-carbohydrate and high-calorie diets compared to normal-weight individuals (P < 0.0001), the influence of the rs7517862 polymorphism on T2D risk was observed independently of these dietary habits. Functional SNP annotation revealed the following: (1) the rs2341471-G allele is associated with increased ATF6 expression; (2) the SNP is located in a region exhibiting enhancer activity epigenetically regulated in pancreatic islets; (3) the rs2341471-G was predicted to create binding sites for 18 activating transcription factors that are part of gene-regulatory networks controlling glucose metabolism and maintaining proteostasis.
CONCLUSIONS: The present study revealed, for the first time, a strong association between the rs2341471-G/G ATF6 genotype and an increased risk of type 2 diabetes in people with obesity or overweight, regardless of known dietary risk factors. Further research is needed to support the potential of silencing the ATF6 gene as a means for the treatment and prevention of type 2 diabetes.